The factor VIII treatment history of non-severe hemophilia A.
factor VIII
hemophilia A
hemorrhage
joint bleed
treatment
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
31
03
2020
revised:
01
08
2020
accepted:
18
08
2020
pubmed:
3
9
2020
medline:
15
5
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
In patients with non-severe hemophilia A, we lack detailed knowledge on the timing of treatment with factor VIII (FVIII) concentrates. This knowledge could provide information about the expected treatment timing in patients with severe hemophilia A treated with non-replacement therapies. To assess the FVIII treatment history in patients with non-severe hemophilia A. Patients with non-severe hemophilia (baseline FVIII activity [FVIII:C] 2-40 IU/dL) were included from the INSIGHT study. The primary outcome was median age at first FVIII exposure (ED1). In a subgroup of patients for whom more detailed information was available, we analyzed the secondary outcomes: median age at first 20 EDs, annualized bleeding rate for all bleeds (ABR), joint bleeds (AJBR), and major spontaneous bleeds (ASmBR). In the total cohort (n = 1013), median baseline FVIII activity was 8 IU/dL (interquartile range [IQR] 4-15) and the median age at ED1 was 3.7 years (IQR 1.4-7.7). Median age at ED1 rose from 2.5 years (IQR 1.2-5.7) in patients with FVIII:C 2-5 IU/dL to 9.7 years (IQR 4.8-16.0) in patients with FVIII:C 25-40 IU/dL. In the subgroup (n = 104), median age at ED1, ED5, ED10, and ED20 was 4.0 years (IQR 1.4-7.6), 5.6 years (IQR 2.9-9.3), 7.5 years (IQR 4.4-11.3), and 10.2 years (IQR 6.5-14.2), respectively. Median ABR, AJBR, and ASmBR were 1.1 (IQR 0.5-2.6), 0.3 (IQR 0.1-0.7), and 0 (IQR 0-0), respectively. This study demonstrates that in non-severe hemophilia A, the age at first FVIII exposure increases with baseline FVIII:C and that major spontaneous bleeds rarely occur.
Sections du résumé
BACKGROUND
In patients with non-severe hemophilia A, we lack detailed knowledge on the timing of treatment with factor VIII (FVIII) concentrates. This knowledge could provide information about the expected treatment timing in patients with severe hemophilia A treated with non-replacement therapies.
OBJECTIVE
To assess the FVIII treatment history in patients with non-severe hemophilia A.
METHODS
Patients with non-severe hemophilia (baseline FVIII activity [FVIII:C] 2-40 IU/dL) were included from the INSIGHT study. The primary outcome was median age at first FVIII exposure (ED1). In a subgroup of patients for whom more detailed information was available, we analyzed the secondary outcomes: median age at first 20 EDs, annualized bleeding rate for all bleeds (ABR), joint bleeds (AJBR), and major spontaneous bleeds (ASmBR).
RESULTS
In the total cohort (n = 1013), median baseline FVIII activity was 8 IU/dL (interquartile range [IQR] 4-15) and the median age at ED1 was 3.7 years (IQR 1.4-7.7). Median age at ED1 rose from 2.5 years (IQR 1.2-5.7) in patients with FVIII:C 2-5 IU/dL to 9.7 years (IQR 4.8-16.0) in patients with FVIII:C 25-40 IU/dL. In the subgroup (n = 104), median age at ED1, ED5, ED10, and ED20 was 4.0 years (IQR 1.4-7.6), 5.6 years (IQR 2.9-9.3), 7.5 years (IQR 4.4-11.3), and 10.2 years (IQR 6.5-14.2), respectively. Median ABR, AJBR, and ASmBR were 1.1 (IQR 0.5-2.6), 0.3 (IQR 0.1-0.7), and 0 (IQR 0-0), respectively.
CONCLUSION
This study demonstrates that in non-severe hemophilia A, the age at first FVIII exposure increases with baseline FVIII:C and that major spontaneous bleeds rarely occur.
Identifiants
pubmed: 32877570
doi: 10.1111/jth.15076
pmc: PMC7756346
pii: S1538-7836(22)03766-7
doi:
Substances chimiques
Hemostatics
0
Factor VIII
9001-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3203-3210Informations de copyright
© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
Références
Thromb Haemost. 2015 Jul;114(1):46-55
pubmed: 25879247
J Thromb Haemost. 2015 Jul;13(7):1217-25
pubmed: 25912309
Haemophilia. 2004 Sep;10(5):560-4
pubmed: 15357784
Expert Opin Biol Ther. 2019 Aug;19(8):801-810
pubmed: 31039049
Haemophilia. 1998 Sep;4(5):714-20
pubmed: 9873876
J Thromb Haemost. 2017 Feb;15(2):246-254
pubmed: 27943580
Blood. 2013 May 16;121(20):4046-55
pubmed: 23553768
Haemophilia. 2011 Nov;17(6):849-53
pubmed: 21545376
J Thromb Haemost. 2020 Dec;18(12):3203-3210
pubmed: 32877570
Blood. 2013 Sep 12;122(11):1954-62
pubmed: 23926300
J Thromb Haemost. 2014 Nov;12(11):1935-9
pubmed: 25059285
J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):32-5
pubmed: 9482410
Thromb Haemost. 2016 Mar;115(3):543-50
pubmed: 26582077
Haemophilia. 2006 Mar;12(2):124-7
pubmed: 16476085
Haemophilia. 2013 Jan;19(1):e1-47
pubmed: 22776238
N Engl J Med. 2007 Aug 9;357(6):535-44
pubmed: 17687129
BMJ. 2012 May 02;344:e2707
pubmed: 22551712
Haemophilia. 2009 May;15(3):665-75
pubmed: 19432921
Blood Adv. 2018 Aug 28;2(16):2136-2144
pubmed: 30143528
Br J Haematol. 2013 Jan;160(2):153-70
pubmed: 23157203
Blood. 2004 Dec 1;104(12):3494-500
pubmed: 15308570
Thromb Haemost. 2001 Mar;85(3):560
pubmed: 11307831
Haemophilia. 2012 Mar;18(2):166-74
pubmed: 21771207
Br J Haematol. 2017 Mar;176(5):796-804
pubmed: 28198996
Thromb J. 2013 Mar 07;11(1):6
pubmed: 23496906
Blood. 2007 Jun 1;109(11):4648-54
pubmed: 17289808